Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
NCT ID: NCT02622646
Last Updated: 2016-08-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
25 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-08-31
Study Completion Date
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Haemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII (FVIII). Patients with severe hemophilia A have a FVIII plasma concentration less than1 IU/dL and experience spontaneous and trauma-induced bleeds. Joint bleeds lead to hemophilic arthropathy resulting in progressive disability. Patients with moderate hemophilia (FVIII level between 1-5 IU/dL) are characterized by fewer hemarthroses, usually trauma-induced, and a decreased likelihood of developing arthropathy. This clinical observation led to the use of prophylactic FVIII infusions to convert patient´s bleeding phenotype from severe to moderate with the result of decreasing or preventing arthropathy.
Prophylactic regimens may be effective when based on standard fixed-dose protocols (that assumes one approach fits all patients) or phenotypic dosing determined by bleeding patterns, but do not protect all patients with severe haemophilia from joint damage caused by spontaneous or activity-triggered bleeding.
Individualized treatment in haemophilia A takes into consideration all available information about the patient, not only his phenotypic bleeding pattern. Some of the factors that contribute to the observed interpatient variability include baseline or residual FVIII activity, the pharmacokinetic (PK) profile of the replacement factor, the individual's level of physical activity and perceived risk of traumatic bleeding, the presence or absence of joint disease, presence of comorbidities and adherence to the dosing regimen.
Objectives:
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®.
2. Analyze differences in PK parameters in non-controlled vs well controlled patients.
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Prophylactic regimens may be effective when based on standard fixed-dose protocols (that assumes one approach fits all patients) or phenotypic dosing determined by bleeding patterns, but do not protect all patients with severe haemophilia from joint damage caused by spontaneous or activity-triggered bleeding.
Individualized treatment in haemophilia A takes into consideration all available information about the patient, not only his phenotypic bleeding pattern. Some of the factors that contribute to the observed interpatient variability include baseline or residual FVIII activity, the pharmacokinetic (PK) profile of the replacement factor, the individual's level of physical activity and perceived risk of traumatic bleeding, the presence or absence of joint disease, presence of comorbidities and adherence to the dosing regimen.
Objectives:
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®.
2. Analyze differences in PK parameters in non-controlled vs well controlled patients.
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
NCT02280265
Hemophilia A
UNKNOWN
NA
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386
Hemophilia A
COMPLETED
PHASE4
Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
NCT00666406
Hemophilia A
COMPLETED
PHASE4
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
NCT02078427
Hemophilia A
COMPLETED
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536
Hemophilia A
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research Question:
* Is standard prophylaxis effective for all hemophilia A patient?
* Which are the causes for poor clinical response in some patients on prophylactic treatment?
* Can differences in PK impact the clinical outcome and effectiveness of prophylaxis?
* For a given group of poor controlled patients in standard prophylaxis, may personalized prophylaxis improve clinical outcome when acting on the specific cause(s)?
Study Background \& Rationale:
Haemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII (FVIII). Patients with severe hemophilia A have a FVIII plasma concentration less than1 IU/dL and experience spontaneous and trauma-induced bleeds. Joint bleeds lead to hemophilic arthropathy resulting in progressive disability. Patients with moderate hemophilia (FVIII level between 1-5 IU/dL) are characterized by fewer hemarthroses, usually trauma-induced, and a decreased likelihood of developing arthropathy. This clinical observation led to the use of prophylactic FVIII infusions to convert patient´s bleeding phenotype from severe to moderate with the result of decreasing or preventing arthropathy.
Prophylactic regimens may be effective when based on standard fixed-dose protocols (that assumes one approach fits all patients) or phenotypic dosing determined by bleeding patterns, but do not protect all patients with severe haemophilia from joint damage caused by spontaneous or activity-triggered bleeding.
Individualized treatment in haemophilia A takes into consideration all available information about the patient, not only his phenotypic bleeding pattern. Some of the factors that contribute to the observed interpatient variability include baseline or residual FVIII activity, the pharmacokinetic (PK) profile of the replacement factor, the individual's level of physical activity and perceived risk of traumatic bleeding, the presence or absence of joint disease, genotype, presence of comorbidities and adherence to the dosing regimen.
The PK response to FVIII varies between patients and this has important clinical implications for treatment. Although PK is affected by patient characteristics, this relationship is too weak to infer a result for an individual and, if required, PK must be measured. An important determinant of the efficacy of prophylaxis is the length of time an individual spends with a low level of coagulation factor.
According to the existing International Society on Thrombosis and Haemostasis (ISTH) guidelines measurement of PK in clinical practice requires in adult patients a total of 8 samples (5 in children) to be taken over a period of 48 h. It requires significant commitment in time from the patient, and family and overnight hospital admission may be required.
The Bayesian estimation method uses a population PK model based on FVIII levels from a large population of patients as a mathematical/ statistical framework to estimate the PK in an individual patient from minimal data. Several studies employed this technique for FVIII in a limited number of patients. Using this strategy, a patient´s coagulation factor half-life may be calculated from two or three time points, reducing the inconvenience to the patient, the discomfort of venipuncture and the cost of sample handing and assays. This methodology can facilitate measurement of PK in routine clinical practice.
Knowledge of the individual's PK response to the replacement factor helps to determine both the dosing level as well as the frequency of administration needed to achieve optimal levels of the deficient hemostatic factor. In particular, achieving ideal peak levels helps reduce the risk of bleeding related to repetitive physical activity, whereas minimizing the time spent at trough levels below 1 IU/dL helps to reduce breakthrough bleeding events . The effect of patient´s FVIII half-life will potentially have a significant impact of prophylactic regimens, whereas changing the frequency of dosing and increasing the dose/kg of FVIII has a smaller effect on the through level.
Different trough levels may be targeted, depending on circumstances: higher levels may be desired to manage target joints, highly active patients, or those more prone to bleeding; alternatively, lower levels may be allowed in a patient who has not bled for a long time.
Last studies demonstrated that the utility of prophylaxis dose tailoring with individual PK with similar results than phenotypic dosing but with fewer infusions, and maybe, this option could increase treatment adherence. Besides, the PK monitoring could be more cost-effective dosing compared to standard dosage.
Adherence to prophylaxis regimens is another patient-specific factor that influences plasma levels and bleeding risk. There are two definitions of adherence in haemophilia, adherence as the percentage of infusions within a specified dose range (adherence to dose) and the percentage of weeks without missed doses (adherence to frequency). Different studies showed that bleedings rate was higher in nonadherent patients, being older patients more likely to miss doses. Strategies to improve adherence would be expected to decrease the number of bleeds, whereas poor adherence make PK dose tailoring irrelevant.
Use of sparse blood sampling and Bayesian analysis for measuring pharmacokinetics, and for the use of this information to tailor doses in prophylaxis has been previously reported. Clinical implementation of these methods with all the available information of the patient (bleeding pattern, joint status, genetic mutation, adherence, etc.), is lacking. Exploratory studies on the use of PK tailored prophylaxis are required to establish the safety and efficacy of this approach. This procedure could allow individualization of treatment by the routine determination of individual pharmacokinetics in the clinic, potentially making prophylaxis more cost-effective.
Primary Endpoint:
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®
2. Analyze differences in PK parameters in non-controlled vs well controlled patients
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Duration of subject participation: One year
Total number of subjects to be enrolled: 25-30 patients
Specific details of Treatment/Intervention:
This prospective, open-label, observational study will be performed at the Hospital Universitari i Politecnic La Fe in Valencia, Spain. This study will include patients with severe and moderate haemophilia A in prophylactic treatment with rFVIII (Advate®).
1. The study will start with the determination of individual PK by sparse blood sampling (2-3 blood samples) and Bayesian analysis (using myPKFiT Medical Device). The PK parameters of the cohort of patients in prophylaxis with Advate® will be described.
2. Patients will be divided in two groups according to the clinical outcome (Bleeding Episodes) in the previous year:
1. Well controlled patients: Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
2. Poor controlled patients: Patients with poor disease control, based on the international guidelines: AJBR\>2, ABR\>2 for severe BE or ABR \>5 for non-severe BE
3. Differences in PK parameters in these 2 groups will be analyzed and compared adjusting by age and weight:
a. Half-life (h) b. Clearance (dl/h) c. Volume on steady state (L) d. Time to FVIII level below 1% (h)
4. Non-controlled patients will be studied and interviewed to identify causes of poor disease control. Patients' individual variables that influence bleeding risk will be studied:
1. Individual PK parameters (See bullet point 3)
2. Bleeding pattern: Haemophilia Severity Score
3. Joint status (Gilbert score and HJHS)
4. Physical activity: Category Risk 1, 2 or 3
5. Patient's adherence: Adherence index (AI)
5. After identifying in each patient the individual cause(s) of poor bleeding control, a "Pilot Program on Personalized Prophylaxis" will be designed to act on the specific factors that may cause bleeding despite prophylaxis.
1. Shorter half-life compared to Advate PK Population (graph displayed in myPKFiT)
• Prophylaxis will be adjusted to individual PK using the recommendation of myPKFiT Medical Device\*.
2. Patients with bleeding phenotype: HSS \>0.79 (for severe HA) or HSS\>0.47 (for moderate HA)
* Prophylaxis will be adjusted to increase through level according to bleeding phenotype\*
3. Patients with joint damage and at least one target joint (at least score of 3 in the Gilbert scale and /or at least score of 3 in the Pettersson scale and/or Chronic synovitis evidenced by ultrasound.) • Prophylaxis will be adjusted to increase through level according to Joint status\*
4. Physical activity: Category \>1
* Prophylaxis will be adjusted to:
<!-- -->
1. Match the day of physical activity with the day of infusion
2. Increase through level according to physical activity\*
e. Patient's with poor adherence:
• Monthly sessions together with the psychologist and pharmacist of the HTC will be scheduled to address adherence issues. myPKFiT displayed graphs will be used to explain availability and elimination of FVIII from the blood.
\*All these dose adjustments will be made not only based on clinical data, but also based on the knowledge and experience of the responsible physician of the patient.
6\. Using a prospective design, patients will be studied during 12 months following the start of the "Personalized Prophylaxis Program". Patient´s clinical state will be assessed at least 2 times per year (normally 2-4 visits per year depending on disease severity).
1. AJBR and ABR (severe, non-severe, spontaneous or traumatic bleeding episodes) will be collected at month 6 and 12.
2. Joint status, Gilbert and HJS will be measures at month 12.
3. Adherence index (AI) will be calculated at month 12
4. Quality of Life will be measures at month 12.
* This study will be conducted without significant changes in medical treatment of patients.
* The study is currently in approval process by the local Clinical Research Ethics Committee and will be conducted in accordance with the declaration of Helsinki and its amendments. An informed consent will be obtained from the patients included in the study.
Statistical Methods:
Statistical analyses will be performed with the R software (version 3.2.2). Data will be described with the mean, standard deviation, median and interquartile range for quantitative variables and relative and absolute frequencies for categorical variables. P-values \< 0.05 will be considered statistically significant. For all the analyses, the Institution's Biostatistical Unit will support this study.
A non-parametric statistical method (Wilcoxon test) will be used for simple comparisons between PK parameters of both groups of patients (clinically controlled and uncontrolled with prophylaxis treatment).
The effects of time below 1 IU/dL, Vss, Cl and half-life on annual bleeding rates (ABR and AJBR) will be analyzed by multivariate analyses in both groups. Multivariate analysis on annual bleeding rates (as a dependent variable) will be performed separately for each of the potential factors associated with bleed rate such as PK parameters, physical activity, adherence to treatment schedule and quality of life. In all instances a regression model utilizing the negative binomial distribution will be used.
Annualized FVIII consumption and rates of treatment related AEs for each prophylaxis group will be compared using a Mann-Whitney U-test.
The sample size of 25-30 patients has been calculated to provide 90% power to detect a mean treatment difference of four ABR or AJBR episodes with two-sided a = 0.05, assuming a standard deviation (SD) of 6 ABR or AJBR episodes in six months. The sample size assumed an ABR variance of at least that observed for compliant subjects in a previous study. Sample size has been calculated using NQUERY, version 5.0, module MOT 1-1 (Statistical Solutions, Saugus, MA, USA).
* Is standard prophylaxis effective for all hemophilia A patient?
* Which are the causes for poor clinical response in some patients on prophylactic treatment?
* Can differences in PK impact the clinical outcome and effectiveness of prophylaxis?
* For a given group of poor controlled patients in standard prophylaxis, may personalized prophylaxis improve clinical outcome when acting on the specific cause(s)?
Study Background \& Rationale:
Haemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII (FVIII). Patients with severe hemophilia A have a FVIII plasma concentration less than1 IU/dL and experience spontaneous and trauma-induced bleeds. Joint bleeds lead to hemophilic arthropathy resulting in progressive disability. Patients with moderate hemophilia (FVIII level between 1-5 IU/dL) are characterized by fewer hemarthroses, usually trauma-induced, and a decreased likelihood of developing arthropathy. This clinical observation led to the use of prophylactic FVIII infusions to convert patient´s bleeding phenotype from severe to moderate with the result of decreasing or preventing arthropathy.
Prophylactic regimens may be effective when based on standard fixed-dose protocols (that assumes one approach fits all patients) or phenotypic dosing determined by bleeding patterns, but do not protect all patients with severe haemophilia from joint damage caused by spontaneous or activity-triggered bleeding.
Individualized treatment in haemophilia A takes into consideration all available information about the patient, not only his phenotypic bleeding pattern. Some of the factors that contribute to the observed interpatient variability include baseline or residual FVIII activity, the pharmacokinetic (PK) profile of the replacement factor, the individual's level of physical activity and perceived risk of traumatic bleeding, the presence or absence of joint disease, genotype, presence of comorbidities and adherence to the dosing regimen.
The PK response to FVIII varies between patients and this has important clinical implications for treatment. Although PK is affected by patient characteristics, this relationship is too weak to infer a result for an individual and, if required, PK must be measured. An important determinant of the efficacy of prophylaxis is the length of time an individual spends with a low level of coagulation factor.
According to the existing International Society on Thrombosis and Haemostasis (ISTH) guidelines measurement of PK in clinical practice requires in adult patients a total of 8 samples (5 in children) to be taken over a period of 48 h. It requires significant commitment in time from the patient, and family and overnight hospital admission may be required.
The Bayesian estimation method uses a population PK model based on FVIII levels from a large population of patients as a mathematical/ statistical framework to estimate the PK in an individual patient from minimal data. Several studies employed this technique for FVIII in a limited number of patients. Using this strategy, a patient´s coagulation factor half-life may be calculated from two or three time points, reducing the inconvenience to the patient, the discomfort of venipuncture and the cost of sample handing and assays. This methodology can facilitate measurement of PK in routine clinical practice.
Knowledge of the individual's PK response to the replacement factor helps to determine both the dosing level as well as the frequency of administration needed to achieve optimal levels of the deficient hemostatic factor. In particular, achieving ideal peak levels helps reduce the risk of bleeding related to repetitive physical activity, whereas minimizing the time spent at trough levels below 1 IU/dL helps to reduce breakthrough bleeding events . The effect of patient´s FVIII half-life will potentially have a significant impact of prophylactic regimens, whereas changing the frequency of dosing and increasing the dose/kg of FVIII has a smaller effect on the through level.
Different trough levels may be targeted, depending on circumstances: higher levels may be desired to manage target joints, highly active patients, or those more prone to bleeding; alternatively, lower levels may be allowed in a patient who has not bled for a long time.
Last studies demonstrated that the utility of prophylaxis dose tailoring with individual PK with similar results than phenotypic dosing but with fewer infusions, and maybe, this option could increase treatment adherence. Besides, the PK monitoring could be more cost-effective dosing compared to standard dosage.
Adherence to prophylaxis regimens is another patient-specific factor that influences plasma levels and bleeding risk. There are two definitions of adherence in haemophilia, adherence as the percentage of infusions within a specified dose range (adherence to dose) and the percentage of weeks without missed doses (adherence to frequency). Different studies showed that bleedings rate was higher in nonadherent patients, being older patients more likely to miss doses. Strategies to improve adherence would be expected to decrease the number of bleeds, whereas poor adherence make PK dose tailoring irrelevant.
Use of sparse blood sampling and Bayesian analysis for measuring pharmacokinetics, and for the use of this information to tailor doses in prophylaxis has been previously reported. Clinical implementation of these methods with all the available information of the patient (bleeding pattern, joint status, genetic mutation, adherence, etc.), is lacking. Exploratory studies on the use of PK tailored prophylaxis are required to establish the safety and efficacy of this approach. This procedure could allow individualization of treatment by the routine determination of individual pharmacokinetics in the clinic, potentially making prophylaxis more cost-effective.
Primary Endpoint:
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®
2. Analyze differences in PK parameters in non-controlled vs well controlled patients
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Duration of subject participation: One year
Total number of subjects to be enrolled: 25-30 patients
Specific details of Treatment/Intervention:
This prospective, open-label, observational study will be performed at the Hospital Universitari i Politecnic La Fe in Valencia, Spain. This study will include patients with severe and moderate haemophilia A in prophylactic treatment with rFVIII (Advate®).
1. The study will start with the determination of individual PK by sparse blood sampling (2-3 blood samples) and Bayesian analysis (using myPKFiT Medical Device). The PK parameters of the cohort of patients in prophylaxis with Advate® will be described.
2. Patients will be divided in two groups according to the clinical outcome (Bleeding Episodes) in the previous year:
1. Well controlled patients: Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
2. Poor controlled patients: Patients with poor disease control, based on the international guidelines: AJBR\>2, ABR\>2 for severe BE or ABR \>5 for non-severe BE
3. Differences in PK parameters in these 2 groups will be analyzed and compared adjusting by age and weight:
a. Half-life (h) b. Clearance (dl/h) c. Volume on steady state (L) d. Time to FVIII level below 1% (h)
4. Non-controlled patients will be studied and interviewed to identify causes of poor disease control. Patients' individual variables that influence bleeding risk will be studied:
1. Individual PK parameters (See bullet point 3)
2. Bleeding pattern: Haemophilia Severity Score
3. Joint status (Gilbert score and HJHS)
4. Physical activity: Category Risk 1, 2 or 3
5. Patient's adherence: Adherence index (AI)
5. After identifying in each patient the individual cause(s) of poor bleeding control, a "Pilot Program on Personalized Prophylaxis" will be designed to act on the specific factors that may cause bleeding despite prophylaxis.
1. Shorter half-life compared to Advate PK Population (graph displayed in myPKFiT)
• Prophylaxis will be adjusted to individual PK using the recommendation of myPKFiT Medical Device\*.
2. Patients with bleeding phenotype: HSS \>0.79 (for severe HA) or HSS\>0.47 (for moderate HA)
* Prophylaxis will be adjusted to increase through level according to bleeding phenotype\*
3. Patients with joint damage and at least one target joint (at least score of 3 in the Gilbert scale and /or at least score of 3 in the Pettersson scale and/or Chronic synovitis evidenced by ultrasound.) • Prophylaxis will be adjusted to increase through level according to Joint status\*
4. Physical activity: Category \>1
* Prophylaxis will be adjusted to:
<!-- -->
1. Match the day of physical activity with the day of infusion
2. Increase through level according to physical activity\*
e. Patient's with poor adherence:
• Monthly sessions together with the psychologist and pharmacist of the HTC will be scheduled to address adherence issues. myPKFiT displayed graphs will be used to explain availability and elimination of FVIII from the blood.
\*All these dose adjustments will be made not only based on clinical data, but also based on the knowledge and experience of the responsible physician of the patient.
6\. Using a prospective design, patients will be studied during 12 months following the start of the "Personalized Prophylaxis Program". Patient´s clinical state will be assessed at least 2 times per year (normally 2-4 visits per year depending on disease severity).
1. AJBR and ABR (severe, non-severe, spontaneous or traumatic bleeding episodes) will be collected at month 6 and 12.
2. Joint status, Gilbert and HJS will be measures at month 12.
3. Adherence index (AI) will be calculated at month 12
4. Quality of Life will be measures at month 12.
* This study will be conducted without significant changes in medical treatment of patients.
* The study is currently in approval process by the local Clinical Research Ethics Committee and will be conducted in accordance with the declaration of Helsinki and its amendments. An informed consent will be obtained from the patients included in the study.
Statistical Methods:
Statistical analyses will be performed with the R software (version 3.2.2). Data will be described with the mean, standard deviation, median and interquartile range for quantitative variables and relative and absolute frequencies for categorical variables. P-values \< 0.05 will be considered statistically significant. For all the analyses, the Institution's Biostatistical Unit will support this study.
A non-parametric statistical method (Wilcoxon test) will be used for simple comparisons between PK parameters of both groups of patients (clinically controlled and uncontrolled with prophylaxis treatment).
The effects of time below 1 IU/dL, Vss, Cl and half-life on annual bleeding rates (ABR and AJBR) will be analyzed by multivariate analyses in both groups. Multivariate analysis on annual bleeding rates (as a dependent variable) will be performed separately for each of the potential factors associated with bleed rate such as PK parameters, physical activity, adherence to treatment schedule and quality of life. In all instances a regression model utilizing the negative binomial distribution will be used.
Annualized FVIII consumption and rates of treatment related AEs for each prophylaxis group will be compared using a Mann-Whitney U-test.
The sample size of 25-30 patients has been calculated to provide 90% power to detect a mean treatment difference of four ABR or AJBR episodes with two-sided a = 0.05, assuming a standard deviation (SD) of 6 ABR or AJBR episodes in six months. The sample size assumed an ABR variance of at least that observed for compliant subjects in a previous study. Sample size has been calculated using NQUERY, version 5.0, module MOT 1-1 (Statistical Solutions, Saugus, MA, USA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hemophilia A
Factor VIII
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Well controlled patients
Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
Recombinant VIII factor
Intervention Type
DRUG
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®
2. Analyze differences in PK parameters in non-controlled vs well controlled patients
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Poor controlled patients
Patients with poor disease control, based on the international guidelines: AJBR\>2, ABR\>2 for severe BE or ABR \>5 for non-severe BE
Recombinant VIII factor
Intervention Type
DRUG
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®
2. Analyze differences in PK parameters in non-controlled vs well controlled patients
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant VIII factor
Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a "personalized pilot program" with a 1 year follow up to act on the specific causes.
1. Describe PK parameters in patients on prophylaxis treatment with Advate®
2. Analyze differences in PK parameters in non-controlled vs well controlled patients
3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults or adolescents older than 12 years
* Patients under Prophylactic treatment with Advate® for at least 1 year
* Written informed consent.
* Patients under Prophylactic treatment with Advate® for at least 1 year
* Written informed consent.
Exclusion Criteria
* History of FVIII inhibitor (titre ≥ 0.6 BU \[Bethesda unit\]) or detectable FVIII inhibitors at screening (titre ≥ 0.4 BU),
* Another haemostatic defect
* Need for major surgery.
* Withdrawal of informed consent
* Another haemostatic defect
* Need for major surgery.
* Withdrawal of informed consent
Minimum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario La Fe
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
José Luis Poveda Andrés
Director of Drug Clinical Area, Hospital Universitari i Politecnic La Fe, Valencia, Spain.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hemostasis and Thrombosis Department, Hospital Universitari i Politecnic La Fe, Valencia, Spain.
Valencia, Valencia, Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Berntorp E, Spotts G, Patrone L, Ewenstein BM. Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014 Apr 5;8:115-27. doi: 10.2147/BTT.S53456. eCollection 2014.
Reference Type
RESULT
Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010 Jul 1;16(4):597-605. doi: 10.1111/j.1365-2516.2009.02191.x. Epub 2010 Feb 9.
Reference Type
RESULT
Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011 Jan;17(1):e239-40. doi: 10.1111/j.1365-2516.2010.02372.x. Epub 2010 Aug 22. No abstract available.
Reference Type
RESULT
Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012 Jan 12;119(2):612-8. doi: 10.1182/blood-2011-07-360594. Epub 2011 Oct 31.
Reference Type
RESULT
Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384.
Reference Type
RESULT
Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Mathieu E, Monagle P, Brown SA. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012 Oct 10;308(14):1452-9. doi: 10.1001/jama.2012.12727.
Reference Type
RESULT
Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20.
Reference Type
RESULT
Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost. 2010 Jan;8(1):83-9. doi: 10.1111/j.1538-7836.2009.03650.x. Epub 2009 Oct 11.
Reference Type
RESULT
Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011 Jan;17(1):2-10. doi: 10.1111/j.1365-2516.2010.02370.x. Epub 2010 Aug 22.
Reference Type
RESULT
Fischer K, Konkle B, Broderick C, Kessler CM. Prophylaxis in real life scenarios. Haemophilia. 2014 May;20 Suppl 4:106-13. doi: 10.1111/hae.12425.
Reference Type
RESULT
Garcia-Dasi M, Aznar JA, Jimenez-Yuste V, Altisent C, Bonanad S, Mingot E, Lucia F, Gimenez F, Lopez MF, Marco P, Perez R, Fernandez MA, Paloma MJ, Galmes B, Herrero S, Garcia-Talavera JA. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia. 2015 Jul;21(4):458-64. doi: 10.1111/hae.12618. Epub 2015 Feb 4.
Reference Type
RESULT
Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991 Sep 2;66(3):384-6. No abstract available.
Reference Type
RESULT
Rodriguez-Merchan EC, Jimenez-Yuste V, Aznar JA, Hedner U, Knobe K, Lee CA, Ljung R, Querol F, Santagostino E, Valentino LA, Caffarini A. Joint protection in haemophilia. Haemophilia. 2011 Sep;17 Suppl 2:1-23. doi: 10.1111/j.1365-2516.2011.02615.x.
Reference Type
RESULT
Ruffo S, Messori A, Grasela TH, Longo G, Donati-Cori G, Matucci M, Morfini M, Tendi E. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed. 1985;19(2-3):167-77. doi: 10.1016/0010-468x(85)90008-x.
Reference Type
RESULT
Schulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J, Blomback M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost. 2008 Jul;6(7):1113-21. doi: 10.1111/j.1538-7836.2008.03001.x. Epub 2008 Jul 1.
Reference Type
RESULT
Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004 Sep;10(5):428-37. doi: 10.1111/j.1365-2516.2004.00932.x.
Reference Type
RESULT
Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x.
Reference Type
RESULT
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014 Sep;20(5):607-15. doi: 10.1111/hae.12438. Epub 2014 Apr 8.
Reference Type
RESULT
Vyas S, Enockson C, Hernandez L, Valentino LA. Towards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institution. Haemophilia. 2014 Jan;20(1):9-14. doi: 10.1111/hae.12227. Epub 2013 Jul 16.
Reference Type
RESULT
Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997 Apr;3(2):96-101. doi: 10.1046/j.1365-2516.1997.00091.x.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUF-OCT-2015-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
NCT00995046
TERMINATED
NA
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
NCT02634723
COMPLETED
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
NCT00782470
COMPLETED
Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
NCT02282410
UNKNOWN
NA
Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
NCT02314325
UNKNOWN
PHASE4
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917
COMPLETED
PHASE3
A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate
NCT04876365
COMPLETED
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934
ACTIVE_NOT_RECRUITING
Hemophilia Inhibitor Previously Untreated Patient Study
NCT01652027
COMPLETED
Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia
NCT05804734
COMPLETED
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019
RECRUITING
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
NCT00486278
COMPLETED
PHASE2
Long-term Anticoagulation in a Patient With Severe Hemophilia A
NCT07314983
RECRUITING
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
NCT02697370
COMPLETED
PHASE4
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A
NCT00916032
COMPLETED
PHASE4
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
NCT01105546
UNKNOWN
PHASE2
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
NCT06864975
RECRUITING
PHASE4
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
NCT00623480
COMPLETED
PHASE3
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
NCT01562587
COMPLETED
PHASE1
ADVATE Post Authorization Safety Surveillance
NCT00214734
COMPLETED
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
NCT01913405
COMPLETED
PHASE3
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934
COMPLETED
Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A
NCT05281185
COMPLETED
PHASE4
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
NCT00952822
COMPLETED
PHASE1